Neurodegenerative disease management最新文献_第2页

Characteristics of responders to interventions for Parkinson disease: a scoping systematic review. 帕金森病干预反应者的特征：范围系统评价。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-30 DOI: 10.1080/17582024.2025.2493465

Sidney T Baudendistel, Gammon M Earhart

{"title":"Characteristics of responders to interventions for Parkinson disease: a scoping systematic review.","authors":"Sidney T Baudendistel, Gammon M Earhart","doi":"10.1080/17582024.2025.2493465","DOIUrl":"https://doi.org/10.1080/17582024.2025.2493465","url":null,"abstract":"Aims: The purpose of this review is to identify the characteristics of responders in interventions targeting motor function for individuals with Parkinson disease.Materials & methods: The primary search included, 'Parkinson' + 'responder.' A second, broader, search further included 'response' + 'responsiveness' + 'responsive.' Records were sorted by intervention: neuromodulation, pharmaceutical, physical, and placebo.Results: Thirteen studies were identified in the primary and 19 studies in the secondary search, culminating in 120 characteristics. For neuromodulation interventions, responders were younger at onset, more responsive to levodopa, and had more difficulties with activities of daily living. Responders to pharmaceuticals were younger at diagnosis. Physical intervention responders had worse balance, less balance confidence, and worse cognition. No relevant characteristics were identified for placebo interventions.Conclusions: Although there are clear limitations and gaps in the literature, responder analyses represent an important step toward more personalized treatments for the motor symptoms of Parkinson disease.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-14"},"PeriodicalIF":2.3,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study. 摩洛哥晚期帕金森病和器械辅助治疗的资格：一项多中心横断面研究

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-03-24 DOI: 10.1080/17582024.2025.2481818

Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani

{"title":"Advanced Parkinson's disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study.","authors":"Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar, Hicham El Otmani","doi":"10.1080/17582024.2025.2481818","DOIUrl":"10.1080/17582024.2025.2481818","url":null,"abstract":"Aim: This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).Methods: We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.Results: This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).Conclusion: Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"65-76"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does menopause affect MS progression? Evidence and ongoing debates. 更年期会影响MS的进展吗？证据和正在进行的辩论。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-07 DOI: 10.1080/17582024.2025.2489878

L Lorefice, E Ferraro

引用次数: 0

Health outcomes and healthcare service use in older adults with and without multiple sclerosis: a plain language summary. 患有和不患有多发性硬化症的老年人的健康结果和保健服务使用：简单的语言总结。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-05-09 DOI: 10.1080/17582024.2025.2488710

Leorah Freeman, Ashlea Lucas, Jia Zhou, Brooke Hayward, Mallory Gough, Terrie Livingston

引用次数: 0

Effect of neuromodulation on neurogenic bladder in women with multiple sclerosis: a pilot randomized controlled trial. 神经调节对多发性硬化症女性神经源性膀胱的影响：一项随机对照试验。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-11 DOI: 10.1080/17582024.2025.2488712

Pınar Atak Çakir, Vahit Güzelburç, Erkingül Birday, Lütfü Hanoğlu, Fatma Mutluay

{"title":"Effect of neuromodulation on neurogenic bladder in women with multiple sclerosis: a pilot randomized controlled trial.","authors":"Pınar Atak Çakir, Vahit Güzelburç, Erkingül Birday, Lütfü Hanoğlu, Fatma Mutluay","doi":"10.1080/17582024.2025.2488712","DOIUrl":"10.1080/17582024.2025.2488712","url":null,"abstract":"Aim: Neurogenic overactive bladder symptoms are very common in patients with multiple sclerosis (MS). In current approaches, neuromodulation methods are preferred. To investigate the effect of transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) on neurogenic overactive bladder symptoms in patients with MS.Patients methods: Sixteen female MS patients with neurogenic overactive bladder were randomized into TPTNS and rTMS groups for a pilot study. Treatment was blinded to the investigator and statistician but not to patients and physiotherapists. Treatments were applied for a total of 10 sessions over two consecutive weeks. The primary outcome of the study was urodynamic testing, and secondary outcomes were Overactive Bladder Questionnaire-V8 (OAB-V8), Incontinence Severity Index (ISI), Incontinence Quality of Life Scale (I-QOL) and voiding diary applied before and after treatment.Results: In TPTNS and rTMS groups, urodynamic parameters did not show any statistically significant change within and between groups (p > 0.05). Only nocturia frequency provided statistically significant improvement in the TPTNS group compared to the rTMS group (p = 0.01). OAB-V8, ISI and I-QOL parameters did not change significantly between groups (p > 0.05).Conclusion: Although TPTNS and rTMS methods are not superior to each other, they can be used to reduce symptoms and improve quality of life.Clinical trial registration: NCT05312138.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"57-64"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort. 利鲁唑对中国ALS队列中生存和ALSFRS变化的真实证据。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-04 DOI: 10.1080/17582024.2025.2488235

JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng

{"title":"Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.","authors":"JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng","doi":"10.1080/17582024.2025.2488235","DOIUrl":"10.1080/17582024.2025.2488235","url":null,"abstract":"Aims: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).Patients & methods: Propensity score matching was used to balance baseline variables between the riluzole group (n = 238) and control group (n = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.Results: Riluzole did not significantly improve survival (p = 0.478) or ALSFRS changes at 6 months (p = 0.380) or 12 months (p = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.Conclusions: Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"77-87"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients. 定量MRI参数对鉴别PSP与MSA的意义探讨。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-03-27 DOI: 10.1080/17582024.2025.2481817

Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu

{"title":"Investigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients.","authors":"Halil Onder, Aynur Turan, Fatmanur Ugur, Selcuk Comoglu","doi":"10.1080/17582024.2025.2481817","DOIUrl":"10.1080/17582024.2025.2481817","url":null,"abstract":"Objective: To investigate the utility of quantitative MRI parkinsonism indices in discriminating between progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) patients.Methods: In our study including PSP and MSA patients, we calculated the radiological measures including superior cerebellar peduncle width, middle cerebellar peduncle width, third ventricle width, 3rdV/bifrontal width, pons/mesencephalon (P/M) ratio, P/M ratio 2.0, magnetic resonance parkinsonism index (MRPI), and MRPI 2.0 values. We also constituted a PMS scale to increase the discrimination power.Results: Comparisons between PSP and MSA patients revealed significant differences in the mesencephalon area, third ventricle width, 3rdV/bifrontal width, P/M ratio, P/M ratio 2.0, MRPI, and MRPI 2.0 values (p < 0.01 for all). The AUC values were acceptable for the third ventricle width, the 3rdV/bifrontal width ratio, the P/M ratio, the P/M 2 ratio, the MRPI and the MRPI-2. In distinguishing PSP, 0 points on the PMS scale had a negative predictive value (NPV) of 91%, whereas 3 points had a positive predictive value (PPV) of 85.7%.Conclusion: None of the MRI parameters reached a good diagnostic AUC in distinguishing PSP from MSA. However, the PMS scale we propose in this study may provide high PPVs and NPVs for differential diagnosis during desk-based evaluation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"89-96"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The calmodulin hypothesis of neurodegenerative diseases: searching for a common cure. 神经退行性疾病的钙调素假说：寻找共同治疗方法。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1080/17582024.2025.2488230

Danton H O'Day

引用次数: 0

Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary. 多发性硬化症的共同决策使用MS-SUPPORT工具：一个简单的语言总结。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-04-01 Epub Date: 2025-05-07 DOI: 10.1080/17582024.2025.2493028

Nananda F Col, Andrew J Solomon, Enrique Alvarez, Lori Pbert, Carolina Ionete, Idanis Berrios Morales, Jennifer Chester, Christen Kutz, Crystal Iwuchukwu, Terrie Livingston, Vicky Springmann, Hannah Col, Long Ngo

引用次数: 0

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. ofatumumab在临床实践中的有效性、持久性、耐受性和安全性。

IF 2.3

Neurodegenerative disease management Pub Date : 2025-02-01 Epub Date: 2025-01-21 DOI: 10.1080/17582024.2025.2452150

Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh

{"title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice.","authors":"Moein Amin, Tucker Harvey, Dan Michael Pineda, Ming-Hui Tai, Qiujun Shao, Brandon Brown, Abhijit Gadkari, Brandon Moss, Devon S Conway, Carrie M Hersh","doi":"10.1080/17582024.2025.2452150","DOIUrl":"10.1080/17582024.2025.2452150","url":null,"abstract":"Aims: To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in a real-world MS population.Patients & methods: Electronic medical records of patients starting OMB from October 2020 to August 2022 at two comprehensive MS centers were reviewed. Demographics and disease characteristics and 6- and 12-month clinical, patient-reported, and radiologic outcome measures were analyzed.Results: A total of 175 patients started OMB with mean age 44.9 (SD 10.4) and disease duration 13.6 (SD 9.6) years. The cohort was 74% female, included 81% White and 13% Black American patients, and consisted of 80% relapsing-remitting MS or clinically isolated syndrome. Most (87%) had prior DMT exposure with 38% switching from high efficacy DMT. Over 12 months, 9.7% discontinued OMB (mean 117 days, SD 99.2), with tolerability issues being the most common reason. Thirty-nine (22%) had relapses in the year before starting OMB. By 12 months, only 1 relapse had occurred after approximately 4 months post-treatment initiation.Discussion: This real-world study demonstrated that OMB is highly effective with robust persistence and good safety and tolerability by 12-month follow-up. Further analyses are planned to examine longer-term outcomes.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"27-36"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0